11 research outputs found
Pharmacogenetics of sunitinib in metastatic renal cell carcinoma
Sunitinib treatment requires a personalized approach,
since patients can respond very differently to this drug. Pharmacogenetics
may improve our ability to provide a tailored therapy by studying how genetic
variations could influence drug response. The objective of this thesis was to
find genetic markers that can predict toxicity and efficacy of sunitinib in
patients with metastatic renal cell carcinoma. This research builds upon
previous findings from candidate gene studies by testing a selection of SNPs
based on plausible involvement in pharmacokinetics or pharmacodynamics of the
drug of interest. We observed that SNPs located in genes involved in
metabolism and drug absorption (CYP3A4, CYP3A5, and ABCB1) are potentially
associated with the clearance of sunitinib and its active metabolite. In
analogy to this, we confirmed SNP associations from previous studies for SNPs
in CYP3A5 and ABCB1 that predict the need for dose reductions and improvement
of PFS on sunitinib. Sunitinib-induced toxicity is possibly related to SNPs
in CYP3A4 and CYP3A5, and in interleukin genes IL8 and IL13. VEGFR-2 (KDR)
rs34231037 G-allele variant carriers were potentially associated with a
favorable response to sunitinib. A GWAS learned us that SNPs in chromosome 21
are involved in sunitinib efficacy, probably by influencing drug resistance
mechanisms.
The research presented in this thesis was performed at the department of Clinical
Pharmacy and Toxicology of Leiden University Medical Center, Leiden, The Netherlands.
Financial support for the publication of this thesis was provided by Afdelingsfonds
Klinische Farmacie & Toxicologie
The research leading to these results has received funding from the European Union’s
Seventh Framework Programme (FP7/2007-2013) under grant agreement no 259939.LUMC / Geneeskund
Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 that correlate with efficacy outcomes in metastatic renal cell carcinoma patients treated with sunitinib
Individual response to sunitinib in metastatic renal cell carcinoma (mRCC) patients is highly variable. Earlier, sunitinib outcome was related to single nucleotide polymorphisms (SNPs) in CYP3A5 and ABCB1. Our aim is to provide novel insights into biological mechanisms underlying sunitinib action. We included mRCC patients from the European EuroTARGET consortium (n = 550) and the RIKEN cohort in Japan (n = 204) which were analysed separately and in a meta-analysis of genome-wide association studies (GWAS). SNPs were tested for association with progression-free survival (PFS) and overall survival (OS) using Cox regression. Summary statistics were combined using a fixed effect meta-analysis. SNP rs28520013 in PDLIM3 and the correlated SNPs rs2205096 and rs111356738 both in DSCAM, showed genome-wide significance (p Personalised Therapeutic
Pharmacogenetics of sunitinib in metastatic renal cell carcinoma
Sunitinib treatment requires a personalized approach,
since patients can respond very differently to this drug. Pharmacogenetics
may improve our ability to provide a tailored therapy by studying how genetic
variations could influence drug response. The objective of this thesis was to
find genetic markers that can predict toxicity and efficacy of sunitinib in
patients with metastatic renal cell carcinoma. This research builds upon
previous findings from candidate gene studies by testing a selection of SNPs
based on plausible involvement in pharmacokinetics or pharmacodynamics of the
drug of interest. We observed that SNPs located in genes involved in
metabolism and drug absorption (CYP3A4, CYP3A5, and ABCB1) are potentially
associated with the clearance of sunitinib and its active metabolite. In
analogy to this, we confirmed SNP associations from previous studies for SNPs
in CYP3A5 and ABCB1 that predict the need for dose reductions and improvement
of PFS on sunitinib. Sunitinib-induced toxicity is possibly related to SNPs
in CYP3A4 and CYP3A5, and in interleukin genes IL8 and IL13. VEGFR-2 (KDR)
rs34231037 G-allele variant carriers were potentially associated with a
favorable response to sunitinib. A GWAS learned us that SNPs in chromosome 21
are involved in sunitinib efficacy, probably by influencing drug resistance
mechanisms.
</p
A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review
Objective: The individual response to targeted tyrosine kinase inhibitors (TKIs) in the treatment of metastatic renal cell cancer (mRCC) is highly variable. Outlined in this article are findings on potential biomarkers for TKI treatment outcome in mRCC and an evaluation of the status of clinical implementation.Methods: Articles were selected by two independent reviewers using a systematic search in five medical databases on renal cell carcinoma, TKIs, and pharmacogenetics.Results: Many researchers have focused on predictive biomarkers for treatment outcome of targeted therapies in mRCC patients. Attempts to explain differences in efficacy and toxicity of TKIs by use of genetic variants in genes related to the pharmacokinetics and pharmacodynamics of the drug have been successful.Conclusion: Most findings on potential biomarkers have not been validated and therefore biomarker testing to guide choice of therapy and dose in mRCC is not yet feasible.Experimentele farmacotherapi
Genetic variants found in paediatric oncology patients with severe chemotherapy-induced toxicity: A case series
Paediatric oncology patients who develop severe chemotherapy-induced toxicity that requires dose reduction, delay or termination of treatment are at risk of decreased treatment efficacy. Previous research has provided evidence that genetic variants in TPMT, NUDT15, UGT1A1 and DPYD are associated with toxicity of anticancer drugs. This led to pharmacogenetic guidelines that are integrated into clinical practice in paediatric oncology. Recently, novel genetic variants have been associated with a higher risk of developing chemotherapy-induced toxicity. In this case series, we selected 21 novel variants and genotyped these in nine patients with excessive chemotherapy-induced toxicity using whole exome sequencing or micro-array data. We observed that six out of nine patients carried at least one variant that, according to recent studies, potentially increased the risk of developing methotrexate- or vincristine-induced toxicity. As patient-derived genetic data are becoming widely accessible in paediatric oncology, these variants could potentially enter clinical practice to mitigate chemotherapy-induced toxicity.Personalised Therapeutic
Logical Imputation to Optimize Prognostic Risk Classification in Metastatic Renal Cell Cancer
CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma
Personalised Therapeutic
A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma
Item does not contain fulltex
Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity
Contains fulltext :
177333.pdf (publisher's version ) (Open Access)OBJECTIVE: For patients with metastatic renal cell cancer (mRCC), treatment choice is mainly based on clinical parameters. With many treatments available and the limited response to treatment and associated toxicities, there is much interest in identifying better biomarkers for personalized treatment. EuroTARGET aims to identify and characterize host- and tumor-related biomarkers for prediction of response to tyrosine kinase inhibitor therapy in mRCC. Here, we describe the EuroTARGET mRCC patient cohort. METHODS AND MATERIALS: EuroTARGET is a European collaborative project designed as an observational study for which patients with mRCC were recruited prospectively in 62 centers. In addition, 462 patients with mRCC from previous studies were included. Detailed clinical information (baseline and follow-up) from all patients was entered in web-based case record forms. Blood was collected for germline DNA and pharmacokinetic/pharmacodynamic analyses and, where available, fresh-frozen tumor material was collected to perform tumor DNA, RNA, kinome, and methylome analyses. RESULTS: In total, 1,210 patients with mRCC were included. Of these, 920 received a tyrosine kinase inhibitor as first-line targeted treatment (sunitinib [N = 713, 78%], sorafenib [N = 41, 4%], or pazopanib [N = 166, 18%]) and had at least 6 months of outcome assessment (median follow-up 15.3 months [interquartile range: 8.5-30.2 months]). Germline DNA samples were available from 824 of these patients, fresh-frozen tumor material from 142 patients, fresh-frozen normal kidney tissue from 95 patients, and tissue microarrays created from formalin-fixed paraffin-embedded tumor material from 247 patients. Of the 920 patients, germline DNA variant chip data were successfully generated for 811 patients (Illumina HumanOmniExpress BeadChip). For 80 patients, next-generation exome sequencing of germline and tumor DNA was performed, tumor RNA sequencing was performed for 124 patients, kinome activity measured and processed for 121 patients (PamChip), and methylome data (Illumina Infinium HumanMethylation450 BeadChip) were created for 116 RCC tissues (and 23 normal kidney tissues). For 73 out of the 920 patients, all platform data types were generated. In addition, 40 patients were included in a pharmacokinetic/pharmacodynamic phase IV substudy. CONCLUSIONS: Analysis of EuroTARGET cohort data will contribute to personalization of therapy for patients with mRCC. The extensive clinical data and multiplatform EuroTARGET data will be freely available